Further, the genomic profile of the HPV16-positive carcinomas, with activating mutations in the PI3K-AKT signaling cascade, wildtype status of TP53, and p16 overexpression, resembles that of HPV-driven disease at other locations with implications for future therapy. This evidence concerns the gene AKT1 and carcinoma.